Intuitive Surgical stock has had a remarkable run both recently and long term. As a result, robotic surgery device maker Intuitive Surgical‘s (ISRG) IBD SmartSelect Composite Rating rose to a near-perfect 97 Wednesday, up from 94 the day before.
Intuitive Surgical Stock Passes Benchmark
The new rating shows the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria. The best stocks tend to have a 95 or better grade as they start a significant move, putting the Sunnyvale, Calif.-based company among the best stocks to buy and watch.
On Tuesday, the company posted a 253% increase in earnings for Q2, to $3.92. It has now posted accelerating EPS gains for four consecutive quarters. Revenue growth rose to 72%, or $1.46 billion, up from 18% growth in the prior report. That also marks four quarters of rising growth.
Commenting on Q2 earnings, CEO Gary Guthart said in the earnings release, “We are pleased with our second quarter procedure growth and financial results.” Guthart said the results “reflect both the demand for high-quality minimally invasive procedures as well as a return to surgeries deferred during the pandemic.”
Intuitive Surgical holds the No. 6 rank among its peers in the Medical-Systems/Equipment industry group. InMode (INMD), Bruker (BRKR) and Hologic (HOLX) are among the top 5 highly-rated stocks in the group.
The stock earns a 91 EPS Rating, meaning its recent quarterly and long-term annual earnings growth is outpacing 91% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
Intuitive Surgical stock is now out of buy range after clearing the 893.89 buy point in a flat base. See if it offers a new buy opportunity, such as a three-weeks tight pattern or a rebound off the 50-day or 10-week line.
YOU MIGHT ALSO LIKE: